Kymera Therapeutics (KYMR) Stock Price, News & Analysis

Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $42.68 to $43.87
• 50-Day Range: $28.14 to $48.60
• 52-Week Range: $19.44 to $53.27
• Volume: 393,426 shs
• Average Volume: 557,010 shs
• Market Capitalization: $2.80 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.11
• Consensus Rating: Buy

Kymera Therapeutics Stock Analysis - MarketRank™

Kymera Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 290th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Kymera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 16 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Kymera Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.79) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kymera Therapeutics is -13.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kymera Therapeutics is -13.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kymera Therapeutics has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.62% of the outstanding shares of Kymera Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kymera Therapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Kymera Therapeutics has recently decreased by 5.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kymera Therapeutics does not currently pay a dividend.

Dividend Growth

Kymera Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.62% of the outstanding shares of Kymera Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kymera Therapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Kymera Therapeutics has recently decreased by 5.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.19

News Sentiment

Kymera Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Kymera Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

MarketBeat Follows

2 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Kymera Therapeutics insiders have bought 1,733.41% more of their company's stock than they have sold. Specifically, they have bought $42,797,348.00 in company stock and sold $2,334,301.00 in company stock.

Percentage Held by Insiders

16.01% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

KYMR Stock Analysis - Frequently Asked Questions

How have KYMR shares performed this year?

Kymera Therapeutics' stock was trading at $40.23 on January 1st, 2025. Since then, KYMR shares have increased by 6.8% and is now trading at $42.96.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) released its earnings results on Friday, May, 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics's revenue was up 114.6% on a year-over-year basis.
Read the conference call transcript.

When did Kymera Therapeutics IPO?

Kymera Therapeutics (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Who are Kymera Therapeutics' major shareholders?

Top institutional investors of Kymera Therapeutics include Jennison Associates LLC (1.27%), TD Asset Management Inc (0.36%), Harbor Capital Advisors Inc. (0.05%) and Clear Harbor Asset Management LLC (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, Venture Fund X LP Atlas, Bvf Partners L P/Il, Bruce Booth, Nello Mainolfi, Bruce N Jacobs, Jared Gollob, Ellen Chiniara, Jeremy G Chadwick, Joanna Horobin, Jeffrey W Albers and Elena Ridloff.
View institutional ownership trends.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KYMR
• CIK: 1815442
• Web: www.kymeratx.com
• Phone: 857-285-5300
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kymera Therapeutics: $59.11
• High Price Target: $70.00
• Low Price Target: $51.00
• Potential Upside/Downside: +37.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$223.86 million
• Net Margins: -409.07%
• Pretax Margin: -409.07%
• Return on Equity: -30.11%
• Return on Assets: -25.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.49
• Quick Ratio: 8.49

Sales & Book Value

• Annual Sales: $47.07 million
• Price / Sales: 59.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.90 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 65,120,000
• Free Float: 54,694,000
• Market Cap: $2.80 billion
• Optionable: Optionable
• Beta: 2.18